Bladder Cancer in Situ
BCG-unresponsive Carcinoma in Situ of the bladder is a type of non-invasive bladder cancer that does not respond to standard BCG therapy, potentially leading to more aggressive treatment options.
Bladder Cancer: ONCOFID-P-B Treatment Study
We are studying a new treatment called ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to standard care. The goal is to see if this treatment can effectively reduce tumors and improve patient outcomes.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have persistent or recurrent bladder cancer (CIS) confirmed by a doctor?
- Are you currently taking any medications that could affect your treatment, like blood thinners or steroids?
- Have you had major surgery in the past 4 weeks?
- Are you pregnant, breastfeeding, or not using effective birth control if you could become pregnant?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Oncofid-P-B
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
CHU Gabriel-Montpied
Urology
Beaumont, France
Pellegrin Hospital
Urology
Bordeaux, France
Centre Hospitalier Universitaire De Lille
Urology
Loos, France
Sponsor: Fidia Farmaceutici S.p.A.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.